Amgen stock rebounds after addressing MariTide concerns

Amgen Inc. (NASDAQ: AMGN), a leading biotechnology company, saw a surge in its stock price as concerns regarding the safety of its obesity drug, MariTide, were addressed. The company denied any bone safety concerns linked to the drug and reassured investors that it is committed to the highest safety standards. This news comes as a relief to shareholders who were worried about the potential impact on the company's financial performance. Amgen's stock gained momentum as investors regained confidence in the company's ability to navigate through challenges and deliver positive results. To make informed investment decisions and take advantage of the stock's growth, professionals at Stocks Prognosis recommend considering buying Amgen's shares.